<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Crysvita, INN-burosumab;</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Yu Mincho";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Annotationtext\,Comment Text Char1 Char\,Comment Text Char Char Char\,Comment Text Char1\, Char";
	mso-style-link:"Comment Text Char\,Annotationtext Char\,Comment Text Char1 Char Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char1\, Char Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,Char";
	mso-style-link:"Caption Char\,Char Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Annotationtext Char\,Comment Text Char1 Char Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char1\, Char Char";
	mso-style-link:"Comment Text\,Annotationtext\,Comment Text Char1 Char\,Comment Text Char Char Char\,Comment Text Char1\, Char";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.ColorfulShading-Accent11, li.ColorfulShading-Accent11, div.ColorfulShading-Accent11
	{mso-style-name:"Colorful Shading - Accent 11";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ColorfulList-Accent11, li.ColorfulList-Accent11, div.ColorfulList-Accent11
	{mso-style-name:"Colorful List - Accent 11";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.CaptionChar
	{mso-style-name:"Caption Char\,Char Char";
	mso-style-link:"Caption\,Char";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TableCellCenter, li.TableCellCenter, div.TableCellCenter
	{mso-style-name:"Table Cell Center";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.apple-converted-space
	{mso-style-name:apple-converted-space;}
p.CM38, li.CM38, div.CM38
	{mso-style-name:CM38;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.PIHeading2, li.PIHeading2, div.PIHeading2
	{mso-style-name:"PI Heading 2";
	mso-style-link:"PI Heading 2 Char";
	margin-top:.25in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.PIHeading2Char
	{mso-style-name:"PI Heading 2 Char";
	mso-style-link:"PI Heading 2";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.normaltextrun
	{mso-style-name:normaltextrun;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.TableCellLeft, li.TableCellLeft, div.TableCellLeft
	{mso-style-name:"Table Cell Left";
	mso-style-link:"Table Cell Left Char";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.TableCellLeftChar
	{mso-style-name:"Table Cell Left Char";
	mso-style-link:"Table Cell Left";
	font-family:"Times New Roman",serif;}
p.TableFootnote, li.TableFootnote, div.TableFootnote
	{mso-style-name:"Table Footnote";
	mso-style-link:"Table Footnote Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.TableFootnoteChar
	{mso-style-name:"Table Footnote Char";
	mso-style-link:"Table Footnote";
	font-family:"Times New Roman",serif;}
p.C-BodyText, li.C-BodyText, div.C-BodyText
	{mso-style-name:"C-Body Text";
	mso-style-link:"C-Body Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.C-BodyTextChar
	{mso-style-name:"C-Body Text Char";
	mso-style-link:"C-Body Text";
	font-family:"Times New Roman",serif;}
p.FigureLegend, li.FigureLegend, div.FigureLegend
	{mso-style-name:"Figure Legend";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.Paragraph, li.Paragraph, div.Paragraph
	{mso-style-name:Paragraph;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:125%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><img width=21 height=18
src="CRYSVITA%20II-10-G%20-%20EN%20annexes%20clean_files/image001.png"
alt="BT_1000x858px"><span lang=EN-GB>This medicinal product is subject to
additional monitoring. This will allow quick identification of new safety
information. Healthcare professionals are asked to report any suspected adverse
reactions. See section 4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1.</span></b><b><span lang=EN-GB>       </span><span
lang=EN-GB>NAME OF THE MEDICINAL PRODUCT</span></b><span
class=MsoCommentReference><span lang=EN-GB> </span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CRYSVITA
10&nbsp;mg solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CRYSVITA
20&nbsp;mg solution for injection </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CRYSVITA
30&nbsp;mg solution for injection </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>CRYSVITA
10&nbsp;mg solution for injection</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 10&nbsp;mg of burosumab in 1&nbsp;ml solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>CRYSVITA
20&nbsp;mg solution for injection </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 20&nbsp;mg of burosumab in 1&nbsp;ml solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>CRYSVITA
30&nbsp;mg solution for injection</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 30&nbsp;mg of burosumab in 1&nbsp;ml solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Burosumab is a
recombinant human monoclonal IgG1 antibody for FGF23 and is produced by
recombinant DNA technology using Chinese hamster ovary (CHO) mammalian cell
culture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipient
with known effect</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 45.91&nbsp;mg sorbitol.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solution for
injection (injection).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clear to
slightly opalescent, colourless to pale brownish-yellowish solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.       </span></b><b><span
lang=EN-GB>CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk41380362"><span
lang=EN-GB>CRYSVITA is indicated for </span><span lang=EN-GB>the treatment of
X-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with
radiographic evidence of bone disease, and in adults.</span></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.2</span></b><b><span lang=EN-GB>     </span><span lang=EN-GB>Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated by a physician experienced in the management of patients with
metabolic bone diseases. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral phosphate
and active vitamin D analogues (e.g. calcitriol) should be discontinued 1 week
prior to initiation of treatment. <a name="_Hlk5180694">Vitamin D replacement
or supplementation with inactive forms may be started or continued as per local
guidelines</a> under monitoring of serum calcium and phosphate. At initiation,
fasting serum phosphate concentration should be below the reference range for
age (see section 4.3). </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><u><span
lang=EN-GB>Dosing in Children and Adolescents aged 1 to 17 years </span></u></i></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
starting dose in children and adolescents aged 1 to 17 years</span><span
lang=EN-GB> </span><span lang=EN-GB>is 0.8&nbsp;mg/kg of body weight given
every two weeks. Doses should be rounded to the nearest 10&nbsp;mg. The maximum
dose is 90&nbsp;mg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After initiation
of treatment with burosumab, fasting serum phosphate should be measured every
2&nbsp;weeks for the first month of treatment, every 4 weeks for the following
2 months and thereafter as appropriate. Fasting serum phosphate should also be
measured 4 weeks after any dose adjustment. If&nbsp;fasting serum phosphate is
within the reference range for age, the same dose should be maintained.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Dose increase</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If fasting serum
phosphate is below the reference range for age, the dose may be&nbsp;increased
stepwise by 0.4&nbsp;mg/kg up to a maximum dose of 2.0 mg/kg (maximum dose of
90 mg). Fasting serum phosphate should be measured 4 weeks after dose
adjustment. Burosumab should not be adjusted more frequently than every 4
weeks.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Dose decrease </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If fasting serum
phosphate is above the reference range for age, the next dose should be
withheld and the fasting serum phosphate reassessed within 4 weeks. The patient
must have fasting serum phosphate below the reference range for age to restart burosumab
at half of the previous dose, rounding the amount as described above. </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Dose Conversion at age 18 years</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Children and adolescents aged 1 to 17 years should be treated using
the dosing guidance outlined above. At 18 years of age the patient should convert
to the adult dose and dosing regimen as outlined below.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><u><span
lang=EN-GB>Dosing in Adults</span></u></i></b></p>

<p class=MsoBodyText><span lang=EN-GB style='color:black;font-style:normal'>The
recommended starting dose in adults is 1.0&nbsp;mg/kg of body weight, rounded
to the nearest 10&nbsp;mg up to a maximum dose of 90&nbsp;mg, given every 4
weeks. </span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>After initiation of treatment with burosumab, fasting serum
phosphate should be measured </span><span lang=EN-GB>every 2&nbsp;weeks for the
first month of treatment, every 4 weeks for the following 2 months and
thereafter as appropriate.</span><span lang=EN-GB style='color:black'> <a
name="_Hlk14772542"> Fasting serum phosphate should be measured 2 weeks after
the previous dose of burosumab. If serum phosphate is within the normal range, </a></span><span
lang=EN-GB>the same dose should be continued. </span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:black'>Dose decrease</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>If serum phosphate is above the upper limit of normal
range, the next dose should be withheld and the serum phosphate level
reassessed within 2 weeks. The patient must have serum phosphate below the
normal range before restarting burosumab. Once serum phosphate is below the
normal range, treatment may be restarted at half the initial starting dose up
to a maximum dose of 40 mg every 4&nbsp;weeks. Serum phosphate should be
reassessed 2 weeks after any change in dose.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><u><span
lang=EN-GB>All Patients</span></u></i></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>To decrease the risk for ectopic mineralisation, it is recommended
that fasting serum phosphate is targeted in the lower end of the normal
reference range for age (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Missed dose </span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Treatments may be administered 3 days either side of the scheduled
treatment date if needed for practical reasons. If a patient misses a dose,
burosumab should be resumed as soon as possible at the prescribed dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Burosumab has
not been studied in patients with renal impairment. Burosumab must not be given
to<i> </i>patients with severe or end stage renal disease (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The safety and efficacy of burosumab in children aged less than one
year have not been established in clinical studies. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Elderly </span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Limited data is available in patients over 65 years of age. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For subcutaneous
use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Burosumab should
be injected in the arm, abdomen, buttock or thigh.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The maximum
volume of medicinal product per injection site is 1.5&nbsp;ml. If more than
1.5&nbsp;ml is required on a given dosing day, the total volume of medicinal
product must be split and administered at two or more different injection
sites. Injection sites should be rotated and carefully monitored for signs of
potential reactions (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For handling of burosumab
before administration, see section 6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3</span></b><b><span
lang=EN-GB>     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section 6.1. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concurrent
administration with oral phosphate, active vitamin D analogues (see section
4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fasting serum
phosphate above the normal range for age due to the risk of hyperphosphatemia
(see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
severe renal impairment or end stage renal disease.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4</span></b><b><span
lang=EN-GB>     </span><span lang=EN-GB>Special warnings and precautions for
use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In order to improve the traceability of biological medicinal
products, the name and the batch number</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>of the
administered product should be clearly recorded within the patient’s records.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Ectopic mineralisation</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ectopic mineralisation, as manifested by nephrocalcinosis, has been
observed in patients with XLH treated with oral phosphate and active vitamin D
analogues; these medicinal products should be stopped at least 1 week prior to
initiating burosumab treatment (see section 4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Monitoring for signs and symptoms of
nephrocalcinosis, e.g. by renal ultrasonography, is recommended at the start of
treatment and every 6 months for the first 12 months of treatment, and annually
thereafter. Monitoring of plasma alkaline phosphatase, calcium, parathyroid
hormone (PTH) and creatinine is recommended every 6 months (every 3 months for
children 1 - 2 years) or as indicated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Monitoring of
urine calcium and phosphate is suggested every 3 months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hyperphosphataemia</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Levels of fasting
serum phosphate  should be monitored due to the risk of hyperphosphatemia. To
decrease the risk for ectopic mineralisation, it is recommended that fasting serum
phosphate is targeted in the lower end of the normal reference range for age. Dose
interruption and/or dose reduction may be required (see section 4.2). Periodic
measurement of post prandial serum phosphate is advised.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Serum parathyroid hormone</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Increases in
serum parathyroid hormone have been observed in some XLH patients during
treatment with burosumab. Periodic measurement of serum parathyroid hormone is
advised.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Injection site reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of burosumab may result in local injection site reactions. Administration
should be interrupted in any patient experiencing severe injection site reactions
(see section 4.8) and appropriate medical therapy administered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hypersensitivity</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Burosumab must
be discontinued if serious hypersensitivity reactions occur and appropriate
medical treatment should be initiated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Excipient with known effect</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
contains 45.91 mg of sorbitol in each vial which is equivalent to 45.91 mg/ml. </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.5</span></b><b><span lang=EN-GB>     Interaction with other medicinal
products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concurrent
administration of burosumab with oral phosphate and active vitamin D analogues
is contraindicated as it may cause an increased risk of hyperphosphatemia and
hypercalcaemia (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Caution should
be exercised when combining burosumab with calcimimetic medicinal products
(i.e. agents that mimic the effect of calcium on tissues by activating the
calcium receptor). Co&#8209;administration of these medicinal products has not
been studied in clinical trials and could potentially exacerbate hypocalcaemia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6</span></b><b><span
lang=EN-GB>     </span><span lang=EN-GB>Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>There are no or limited amount of data from the use of burosumab in
pregnant women.</span></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Studies in animals have shown reproductive toxicity (see
section&nbsp;5.3). </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Burosumab is not recommended during pregnancy and in women of
childbearing potential not using contraception. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>It is unknown whether burosumab/metabolites are excreted in human
milk. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A risk to
newborns/infants cannot be excluded.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A decision must
be made whether to discontinue breast-feeding or to discontinue/abstain from burosumab
therapy taking into account the benefit of breast feeding for the child and the
benefit of therapy for the woman.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies in
animals have shown effects on male reproductive organs (see section 5.3). There
are no clinical data available on the effect of burosumab on human fertility.
No specific fertility studies in animals with burosumab were conducted.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7     Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN>Burosumab may have a minor influence on the ability to drive and use
machines. Dizziness may occur following administration of burosumab.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><a
name="_Hlk4584606"><u><span lang=EN-GB>Summary of the safety profile</span></u></a></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>The most common (&gt;10%) adverse drug reactions reported
in paediatric patients treated for up to 64 weeks during clinical trials were: injection
site reactions (56%), cough (56%), </span><span lang=EN-GB>headache (50%),
pyrexia (43%), pain in extremity (40%), vomiting (39%), tooth abscess (35%),
vitamin D decreased <u>(</u>32%), diarrhoea (25%), rash (24%), nausea (15%),
constipation (11%), dental caries (11%) and myalgia (11%). </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>The most common adverse drug reactions reported in adult
patients during clinical trials were: back pain (23%), headache (21%), tooth
infection (19%), restless legs syndrome (13%), muscle spasms (12%), vitamin D
decrease (15%) and dizziness (11%).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>(See section 4.4 and ‘</span><span lang=EN-GB>Description
of selected adverse reactions’ below).</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The adverse reactions are presented by system organ class and
frequency categories, defined using the following convention: very common
(&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon (&#8805;1/1000 to
&lt;1/100); rare (&#8805;1/10,000 to &lt;1/1000); very rare (&lt;1/10,000), not
known (cannot be estimated from the available data). Within each frequency
grouping, undesirable effects are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>An overview of adverse
reactions observed from clinical trials in paediatric patients is presented in Table&nbsp;1.
</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption style='margin-left:42.55pt;text-indent:-42.55pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>Table </span><span lang=EN-GB style='font-size:11.0pt'>1</span><span lang=EN-GB style='font-size:
11.0pt'>:</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt'>Adverse reactions reported in paediatric
patients with XLH based on clinical studies UX023-CL201, UX023-CL205 and UX023-CL301
(N=94)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="37%" valign=top style='width:37.5%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>MedDRA System Organ Class</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.16%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Frequency
  category</span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Adverse
  reaction</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="37%" style='width:37.5%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Tooth abscess<sup>1</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="37%" style='width:37.5%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Cough<sup>2</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="37%" rowspan=2 style='width:37.5%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Headache</span></p>
  </td>
 </tr>
 <tr>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Common </span></p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Dizziness<sup>3</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="37%" style='width:37.5%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Gastrointestinal Disorders</span></p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Vomiting</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Nausea</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Diarrhoea</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Constipation</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Dental Caries</span></p>
  </td>
 </tr>
 <tr style='height:2.05pt'>
  <td width="37%" style='width:37.5%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:2.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:2.05pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:2.05pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Rash<sup>4</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="37%" rowspan=2 style='width:37.5%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width="29%" rowspan=2 style='width:29.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Myalgia </span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Pain in
  extremity</span></p>
  </td>
 </tr>
 <tr>
  <td width="37%" style='width:37.5%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Injection site
  reaction<sup>5</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Pyrexia</span></p>
  </td>
 </tr>
 <tr>
  <td width="37%" style='width:37.5%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Vitamin D
  decreased<sup>6</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><sup><span
lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></sup></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><sup><span
lang=EN-GB style='font-size:9.0pt'>1</span></sup><span lang=EN-GB
style='font-size:9.0pt'>Tooth abscess includes: <i>Tooth abscess, Tooth
infection and Toothache</i></span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><sup><span
lang=EN-GB style='font-size:9.0pt'>2</span></sup><span lang=EN-GB
style='font-size:9.0pt'>Cough includes: <i>Cough, and Productive cough</i></span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><sup><span
lang=EN-GB style='font-size:9.0pt'>3</span></sup><span lang=EN-GB
style='font-size:9.0pt'>Dizziness includes: <i>Dizziness, and Dizziness
exertional</i></span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><sup><span
lang=EN-GB style='font-size:9.0pt'>4</span></sup><span lang=EN-GB
style='font-size:9.0pt'>Rash includes:<i> Rash, Rash erythematous, Rash
generalised, Rash pruritic, Rash maculo-papular, and Rash pustular</i> </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><sup><span
lang=EN-GB style='font-size:9.0pt'>5</span></sup><span lang=EN-GB
style='font-size:9.0pt'>Injection site reaction includes: <i>Injection site
reaction, Injection site erythema, Injection site pruritus, Injection site
swelling, Injection site pain, Injection site rash, Injection site bruising,
Injection site discolouration, Injection site discomfort, Injection site
haematoma, Injection site haemorrhage, Injection site induration, Injection
site macule, and Injection site urticaria</i></span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><sup><span
lang=EN-GB style='font-size:9.0pt'>6</span></sup><span lang=EN-GB
style='font-size:9.0pt'>Vitamin D decreased includes: <i>Vitamin D deficiency,
Blood 25-hydroxycholecalciferol decreased, and Vitamin D decreased</i></span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>An overview of adverse
reactions observed from clinical trials in adults is presented in Table 2.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Table 2: Adverse reactions reported in
adults with XLH (N=176)</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="37%" valign=top style='width:37.5%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>MedDRA
  System Organ Class</b></p>
  </td>
  <td width="29%" valign=top style='width:29.16%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b>Frequency Category</b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b>Adverse Reaction</b></p>
  </td>
 </tr>
 <tr>
  <td width="37%" style='width:37.5%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Infections
  and infestations</p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Very common</p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Tooth infection<sup>1</sup></p>
  </td>
 </tr>
 <tr>
  <td width="37%" rowspan=3 style='width:37.5%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Nervous
  system disorders</p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Very common</p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Headache<sup>2</sup></p>
  </td>
 </tr>
 <tr>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Very common</p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Dizziness</p>
  </td>
 </tr>
 <tr>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Very common</p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Restless legs syndrome</p>
  </td>
 </tr>
 <tr>
  <td width="37%" style='width:37.5%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Gastrointestinal
  disorders</p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Common</p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Constipation</p>
  </td>
 </tr>
 <tr>
  <td width="37%" rowspan=2 style='width:37.5%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Musculoskeletal
  and connective tissue disorders</p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Very common</p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Back pain</p>
  </td>
 </tr>
 <tr>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Very Common</p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Muscle spasms</p>
  </td>
 </tr>
 <tr>
  <td width="37%" rowspan=2 style='width:37.5%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Investigations</p>
  </td>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Very common</p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Vitamin D decreased<sup><span lang=EN-GB>3</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width="29%" style='width:29.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Common</p>
  </td>
  <td width="33%" style='width:33.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'>Blood phosphorus increased<sup>4</sup></p>
  </td>
 </tr>
</table>

<p class=TableCellLeft style='margin:0in'><sup><span style='font-size:8.0pt;
color:black'>&nbsp;</span></sup></p>

<p class=TableCellLeft style='margin:0in'><sup><span style='font-size:8.0pt;
color:black'>1</span></sup><sup><span style='font-size:8.0pt;font-family:"Arial",sans-serif;
color:black'> </span></sup><span style='font-size:9.0pt;color:black'>Tooth
infection includes: <i>tooth abscess and tooth infection</i></span></p>

<p class=TableCellLeft style='margin:0in'><sup><span style='font-size:8.0pt;
color:black'>2 </span></sup><span style='font-size:9.0pt;color:black'>Headache
includes<i>: headache and head discomfort</i> </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><sup><span
lang=EN-GB style='font-size:8.0pt'>3</span></sup><span lang=EN-GB
style='font-size:9.0pt'>Vitamin D decreased includes: <i>Vitamin D deficiency,
Blood 25-hydroxycholecalciferol decreased, and Vitamin D decreased</i></span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><sup><span lang=EN-GB style='font-size:
8.0pt'>4</span></sup><span lang=EN-GB style='font-size:9.0pt'>Blood phosphorus
increased includes:</span><i><span lang=EN-GB> </span></i><i><span lang=EN-GB
style='font-size:9.0pt'>blood phosphorus increased, and hyperphosphataemia</span></i></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Description of selected adverse reactions </span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Injection site reactions</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Paediatric patients:</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Local reactions (e.g. injection site urticaria,
erythema, rash, swelling, bruising, pain, pruritus, and haematoma) have
occurred at the site of injection. In the paediatric studies, approximately 56%
of the patients had an injection site reaction. The injection site reactions
were generally mild in severity, occurred within 1 day of medicinal product
administration, lasted approximately 1 to 3 days, required no treatment, and
resolved in almost all instances.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Adult patients:</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>The frequency of injection site reactions was 12% in
both burosumab and placebo treatment groups (injection site reaction, erythema,
rash, bruising, pain, pruritis and haematoma).  The injection site reactions
were generally mild in severity, occurred within 1 day of medicinal product injection,
lasted approximately 1 to 3 days, required no treatment, and resolved in almost
all instances.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Hypersensitivity</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Paediatric patients:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Hypersensitivity reactions (including:<i> </i></span><span
lang=EN-GB>injection site rash, rash, urticaria, swelling face, dermatitis)
were reported in 18% of paediatric patients. All reported reactions were mild
or moderate in severity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Adult patients:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The incidence of potential hypersensitivity reactions was similar
(6%) in the burosumab treated and placebo treated adults.  The events were mild
to moderate in severity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Vitamin D Decreased</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Paediatric patients:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><a
name="_Hlk5180881"><span lang=EN-GB>Reduced serum 25 hydroxy-vitamin D has been
observed </span></a><span lang=EN-GB>following initiation of burosumab
treatment in approximately 8% of paediatric patients, possibly due to increased
conversion to activated 1,25 dihydroxy-vitamin D.  Supplementation with
inactive vitamin D was successful in restoring plasma levels to normal. </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i>Hyperphosphataemia</i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Adult patients:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><a
name="_Hlk35440953"><span lang=EN-GB>In the double-blind period of Study
UX023-CL303, in the burosumab group during the</span></a></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Placebo-controlled Treatment Period, 9 subjects (13.2%) had high
serum phosphate at least</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:7.35pt;margin-bottom:
.05pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;
line-height:95%'><span lang=EN-GB>once; 5 of these 9 required
protocol-specified dose reduction(s). After initiation of burosumab in the
open-label Treatment Continuation Period, 8 subjects (12.1%) in the
placebo&#8594;burosumab group had high serum phosphate levels. Four of these 8
subjects required protocol-specified dose reduction(s).  The dose for all
patients meeting the protocol-specified criteria was reduced by 50%. A single
patient (1%) required a second dose reduction for continued hyperphosphataemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Restless legs syndrome</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Adult patients:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In adults, approximately 12% of the burosumab treatment group and 8%
in the placebo group had a worsening of baseline restless legs syndrome or new
onset restless legs syndrome of mild to moderate severity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Immunogenicity: </span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Paediatric and adult patients</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:.15pt;
margin-left:.5pt;text-indent:-.5pt;line-height:103%'><span style='color:black'>Overall,
the incidence</span><span style='color:black'> of anti-drug antibodies </span><span
style='color:black'>(ADA)</span><span style='color:black'> to </span><span
style='color:black'>burosumab was &lt;10% in adults and paediatric subjects
administered burosumab. The incidence of neutralising ADA was 3.2% and neutralising
ADA were only found in paediatric subjects. No </span><span style='color:black'>adverse
events</span><span style='color:black'>,</span><span style='color:black'> loss
of efficacy</span><span lang=EN-GB>, or changes in pharmacokinetics profile</span><span
style='color:black'> were associated with these findings. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It&nbsp;allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:lightgrey'>the national reporting system</span> <span
style='color:black;background:#BFBFBF'>listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9</span></b><b><span lang=EN-GB>     </span><span
lang=EN-GB>Overdose</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
experience with overdose of burosumab. Burosumab has been administered in
paediatric clinical trials without dose limiting toxicity using doses up to
2.0&nbsp;mg/kg body weight <span style='color:black;background:white'>with a
maximal dose of 90 mg every two weeks. </span>In adult clinical trials no dose
limiting toxicity has been observed using doses up to 1.0 mg/kg or a maximal
total dose of 128 mg every 4 weeks<span style='color:black;background:white'>.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Management</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of overdose, it is recommended to stop burosumab and to
monitor biochemical response.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.</span></b><b><span
lang=EN-GB>       </span><span lang=EN-GB>PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1</span></b><b><span
lang=EN-GB>     </span><span lang=EN-GB>Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Drugs for the treatment of bone diseases, other drugs affecting bone
structure and mineralisation, ATC code: M05BX05.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Burosumab is a recombinant human monoclonal antibody (IgG1) that
binds to and inhibits the activity of fibroblast growth factor 23 (FGF23). By
inhibiting FGF23, burosumab increases tubular reabsorption of phosphate from
the kidney and increases serum concentration of 1,25&nbsp;dihydroxy&#8209;Vitamin
D.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Clinical efficacy in paediatric patients with XLH</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Study UX023-CL301</span></u></i></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>In
paediatric study UX023-CL301 61 patients aged 1 to 12 years (56% female; 44%
male, Age at first dose, mean (SD): 6.3 (3.31) years) were randomised to
burosumab (n=29) or active control (n=32; oral phosphate and active vitamin D).
At entry to the study all patients had to have had a minimum of 6 months
treatment of oral phosphate and active vitamin D. All patients had radiographic
evidence of bone disease due to XLH</span><span lang=EN-GB style='font-style:
normal'> </span><span lang=EN-GB style='color:windowtext;font-style:normal'>(Rickets
severity score &#8805;2).  Burosumab was started at a dose of 0.8 mg/kg every 2
weeks and increased to 1.2 mg/kg if there was inadequate response, as measured
by fasting serum phosphate.  Those patients randomised to active control group
received multiple daily doses of oral phosphate and active vitamin D.   </span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>The
primary efficacy endpoint was the change in severity of rickets at Week 40, as
assessed by the RGI-C (Radiographic Global Impression of change)</span><span
lang=EN-GB> </span><span lang=EN-GB style='color:windowtext;font-style:normal'>score,
compared between the burosumab and active control groups.  </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The RGI-C is a relative rating scale that compares a patient’s
rickets before and after treatment utilising a 7-point ordinal scale to
evaluate change in the same abnormalities rated in the RSS (as described
below). Scores range from -3 (indicating severe worsening of rickets) to +3
(indicating complete healing of rickets). </span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext;font-style:normal'>The severity of paediatric rickets
was measured using the RSS, a radiographic scoring method based on the degree
of metaphyseal fraying, concavity, and the proportion of the growth plate
affected. In the UX023-CL301 study, the RSS was scored using a predefined scale
looking at specific </span><span lang=EN-GB style='color:windowtext;font-style:
normal'>abnormalities in the wrists and knees. </span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>All
patients completed at least 64 weeks of randomised treatment, no patients had
dose reductions and 8 (28%) of burosumab-treated patients received dose
escalations to 1.2 mg/kg.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Primary Efficacy Results</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Greater healing of rickets at Week 40 was seen with burosumab
treatment compared to active control and this effect was maintained at week 64,
as shown in</span><span lang=EN-GB> Figure 1.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt'>&nbsp;</span></p>

<p class=MsoCaption style='margin-left:42.55pt;text-indent:-42.55pt;page-break-after:
avoid'><a name="_Toc531854490"></a><a name="_Ref514775561"><span lang=EN-GB
style='font-size:11.0pt'>Figure</span></a><span lang=EN-GB style='font-size:
11.0pt'> 1: RGI-C Global Score (Mean ± SE) – Primary Efficacy Endpoint at Week
40 and 64 (Full Analysis Set)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
width=605 height=431 id="Picture 1"
src="CRYSVITA%20II-10-G%20-%20EN%20annexes%20clean_files/image002.jpg"></span><u><span
lang=EN-GB><br clear=all style='page-break-before:always'>
</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Secondary Efficacy Results</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Key Secondary efficacy endpoint results are presented in Table 3.  </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><b><span lang=EN-GB>Table 3: Secondary
Efficacy Endpoint Results </span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=150 valign=top style='width:112.25pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Endpoint</span></b></p>
  </td>
  <td width=74 valign=top style='width:55.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Week</span></b></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Active Control</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>LS
  Mean (SE)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border:solid windowtext 1.0pt;
  border-left:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>Burosumab</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>LS Mean (SE)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB> </span><b>Difference</b>
  <span lang=EN-GB>(burosumab – active control)</span></p>
  </td>
 </tr>
 <tr>
  <td width=150 rowspan=2 style='width:112.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Lower Limb Deformity; assessed by RGI-C</span></p>
  <p class=MsoNormal><span lang=EN-GB> (GEE model)</span></p>
  </td>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>40</span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+0.22 (0.080)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>+0.62 (0.153)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+0.40 [95% CI: 0.07, 0.72] </span></p>
  <p class=MsoNormal><span lang=EN-GB>p&nbsp;= 0.0162</span></p>
  </td>
 </tr>
 <tr>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>64</span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+0.29 (0.119)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'> +1.25 (0.170)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+0.97 [95% CI: +0.57, +1.37] </span></p>
  <p class=MsoNormal><span lang=EN-GB>p &lt;0.0001 </span></p>
  </td>
 </tr>
 <tr>
  <td width=150 rowspan=3 style='width:112.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Height; Z-score </span></p>
  </td>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Baseline</span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>-2.05 (0.87)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>-2.32 (1.17)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>40<sup> a</sup></span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+0.03 (0.031)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>+0.16 (0.052)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+0.12 [95% CI: 0.01, 0.24] </span></p>
  <p class=MsoNormal><span lang=EN-GB>p = 0.0408 </span></p>
  </td>
 </tr>
 <tr>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>64<sup> b</sup></span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+0.02 (0.035)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>+0.17 (0.066)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+0.14 [95% CI: 0.00, 0.29]</span></p>
  <p class=MsoNormal><span lang=EN-GB>p = 0.0490 </span></p>
  </td>
 </tr>
 <tr>
  <td width=150 rowspan=3 style='width:112.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rickets
  severity, RSS total Score </span></p>
  </td>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Baseline</span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>3.19 (1.141)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>3.17 (0.975)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>40<sup> a</sup></span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>-0.72 (0.162)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>-2.08 (0.104)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>-1.34 [95% CI:</span></p>
  <p class=MsoNormal><span lang=EN-GB>1.74, -0.94] p&nbsp;&lt;&nbsp;0.0001 </span></p>
  </td>
 </tr>
 <tr>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>64<sup> b</sup></span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>-1.01 (0.151)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>-2.23 (0.117)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>-1.21 [95% CI: </span></p>
  <p class=MsoNormal><span lang=EN-GB>-1.59, -0.83] p&nbsp;&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=150 rowspan=3 style='width:112.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Serum ALP
  (U/L)</span></p>
  </td>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Baseline</span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>523 (154)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>511 (125)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>40<sup> a</sup></span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>489 (189)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>381 (99)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>-97 [95% CI: </span></p>
  <p class=MsoNormal><span lang=EN-GB>-138, -56] p&nbsp;&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>64<sup> b</sup></span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>495 (182)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>337 (86)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>-147 [95% CI:</span></p>
  <p class=MsoNormal><span lang=EN-GB> -192, -102] p&nbsp;&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=150 rowspan=3 style='width:112.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Six Minute
  Walk Test (m) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Baseline</span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>450 (106)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>385 (86)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>40<sup> a</sup></span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+4 (14)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>+47 (16)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+43 [95% CI:</span></p>
  <p class=MsoNormal><span lang=EN-GB>-0.3, 87] </span></p>
  <p class=MsoNormal><span lang=EN-GB>p = 0.0514</span></p>
  </td>
 </tr>
 <tr>
  <td width=74 valign=top style='width:55.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>64<sup> b</sup></span></p>
  </td>
  <td width=127 valign=top style='width:95.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+29 (17)</span></p>
  </td>
  <td width=135 valign=top style='width:101.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>+75 (13)</span></p>
  </td>
  <td width=118 valign=top style='width:88.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>+46 [95% CI: </span></p>
  <p class=MsoNormal><span lang=EN-GB>2, 89] </span></p>
  <p class=MsoNormal><span lang=EN-GB>p = 0.0399</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>a: the </span><span
style='font-size:9.0pt'>change from Baseline to Week 40 from ANCOVA model.</span></p>

<p class=MsoNormal><span style='font-size:9.0pt'>b</span><span lang=EN-GB
style='font-size:9.0pt'>: the change</span><span style='font-size:9.0pt'> from
Baseline to Week 64 from </span><span lang=EN-GB style='font-size:9.0pt'>GEE
Model</span><span style='font-size:9.0pt'>.</span></p>

<p class=MsoNormal><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<i><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></i>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB style='color:black'>Serum Phosphate</span></i></p>

<p class=MsoBodyText style='page-break-after:avoid'><a name="_Toc482969445"></a><a
name="_Toc531854485"></a><a name="_Ref478490551"><span lang=EN-GB
style='color:windowtext;font-style:normal'>At each study visit at which serum
phosphate was assessed in both groups, changes in serum phosphate from Baseline
were larger in the burosumab group compared with the active control group (p
&lt; 0.0001; GEE model) (Figure 2).</span></a></p>

<p class=MsoCaption style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption style='margin-left:42.55pt;text-indent:-42.55pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>Figure&nbsp;</span><span
lang=EN-GB style='font-size:11.0pt'>2</span><span lang=EN-GB style='font-size:
11.0pt'>: </span><span style='font-size:11.0pt'>Serum Phosphate Concentration
and Change from Baseline (mg/dL) (Mean&nbsp;±&nbsp;SE) by Treatment Group (PD
Analysis Set)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:9.0pt'>Note: Dashed line in figure indicates the lower limit
of the serum phosphate reference range, 3.2 mg/dL (1.03 mmol/L)</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:12.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:12.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><img border=0 width=605 height=415 id="Picture 3"
src="CRYSVITA%20II-10-G%20-%20EN%20annexes%20clean_files/image003.jpg"></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:12.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB>Study UX023-CL201</span></u></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In paediatric Study UX023-CL201, 52 paediatric patients aged 5 to 12
years&nbsp;(mean 8.5 years; SD 1.87) with XLH were treated for 64&nbsp;weeks.
Nearly all patients had radiographic evidence of rickets at baseline and had
received prior oral phosphate and vitamin D analogues for a mean (SD) duration
of 7&nbsp;(2.4) years</span><span lang=EN-GB style='font-family:"Arial",sans-serif'>.
</span><span lang=EN-GB>This </span>conventional therapy was discontinued 2-4
weeks prior to burosumab initiation. <span lang=EN-GB>The burosumab dose was
adjusted to target a fasting serum phosphate concentration of 3.50 to&nbsp;5.02
mg/dL (1.13 to 1.62 mmol/L). Twenty six of 52 patients received burosumab every
4 weeks (Q4W). Twenty six of 52&nbsp;patients received </span><span lang=EN-GB>burosumab</span><span
lang=EN-GB> every two weeks (Q2W) at an average dose (min, max) of 0.73 (0.3,
1.5), 0.98 (0.4, 2.0) and 1.04&nbsp;(0.4, 2.0)&nbsp;mg/kg at weeks 16, 40 and
60 respectively, and up to a maximum dose of 2.0&nbsp;mg/kg. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Burosumab increased serum phosphate concentration and increased
TmP/GFR. In the group that received burosumab every 2 weeks, mean (SD) serum
phosphate concentration increased from 2.38 (0.405) mg/dL (0.77 (0.131) mmol/L)
at baseline), to 3.3 (0.396) mg/dL (1.07 (0.128) mmol/L) at Week 40 and was
maintained to Week 64 at 3.35 (0.445) mg/dL (1.08 (0.144) mmol/L).</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Alkaline phosphatase activity</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Mean (SD) serum total alkaline phosphatase activity was
459 (105) U/L at baseline and decreased to 369 (76) U/L at Week 64 (-19.6%, p
&lt; 0.0001). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Bone-derived serum alkaline phosphatase content was 165
(52) &#956;g/L [mean (SD)] at Baseline and 115&nbsp;(31) &#956;g/L at Week 64
(mean change: -28.5%).</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>The
severity of paediatric rickets in Study UX023-CL201 was measured using the RSS,
as described above. In Study UX023-CL201, the RSS was scored using a predefined
scale looking at specific </span><span lang=EN-GB style='color:windowtext;
font-style:normal'>abnormalities in the wrists and knees. </span><span
lang=EN-GB style='color:windowtext;font-style:normal'>As a complement to the
RSS assessment, the RGI-C rating scale was used. Results are summarised in
Table 4. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Table 4: Rickets Response in Children 5-12 Years
Receiving Burosumab in Study UX023-CL201</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr>
  <td width="27%" rowspan=2 style='width:27.28%;border:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=TableCellCenter align=left style='margin-bottom:1.0pt;text-align:
  left;page-break-after:avoid'><b><span style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width="12%" rowspan=2 valign=top style='width:12.8%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  style='font-size:11.0pt'>Duration of Burosumab</span></b></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  style='font-size:11.0pt'>(week)</span></b></p>
  </td>
  <td width="59%" colspan=2 valign=top style='width:59.92%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  style='font-size:11.0pt'>Effect Size </span></b></p>
  </td>
 </tr>
 <tr>
  <td width="27%" style='width:27.42%;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  style='font-size:11.0pt'>Q2W (N=26)</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.5%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  style='font-size:11.0pt'>Q4W (N=26)</span></b></p>
  </td>
 </tr>
 <tr style='height:14.3pt'>
  <td width="27%" rowspan=3 style='width:27.28%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.9pt 0in 2.9pt;height:14.3pt'>
  <p class=TableCellCenter align=left style='margin-bottom:1.0pt;text-align:
  left;page-break-after:avoid'><b><span style='font-size:11.0pt'>RSS Total
  Score</span></b><span style='font-size:11.0pt'> </span></p>
  <p class=TableCellCenter align=left style='margin-bottom:1.0pt;text-align:
  left;page-break-after:avoid'><span style='font-size:11.0pt'>Baseline Mean
  (SD)</span></p>
  <p class=TableCellCenter align=left style='margin-bottom:1.0pt;text-align:
  left;page-break-after:avoid'><span style='font-size:11.0pt'>LS Mean change
  (SE) from baseline in total score<sup>a</sup> (reduced RSS score indicates
  improvement in rickets severity)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.8%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:14.3pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="27%" style='width:27.42%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt;height:14.3pt'></td>
  <td width="32%" valign=top style='width:32.5%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:14.3pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.6pt'>
  <td width="12%" valign=top style='width:12.8%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:12.6pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'> 40</span></p>
  </td>
  <td width="27%" style='width:27.42%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt;height:12.6pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>1.92 (1.2)</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>-1.06 (0.1)   (p&lt;0.0001)</span></p>
  </td>
  <td width="32%" valign=top style='width:32.5%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:12.6pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>1.67 (1.0)</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>-0.73 (0.1)   (p&lt;0.0001)</span></p>
  </td>
 </tr>
 <tr style='height:16.2pt'>
  <td width="12%" valign=top style='width:12.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:16.2pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'> 64</span></p>
  </td>
  <td width="27%" style='width:27.42%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt;height:16.2pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>-1.00 (0.1)  (p&lt;0.0001)</span></p>
  </td>
  <td width="32%" style='width:32.52%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:16.2pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>-0.84 (0.1)  (p&lt;0.0001)</span></p>
  </td>
 </tr>
 <tr style='height:64.45pt'>
  <td width="27%" style='width:27.28%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt;height:64.45pt'>
  <p class=TableCellCenter align=left style='margin-bottom:1.0pt;text-align:
  left;page-break-after:avoid'><b><span style='font-size:11.0pt'>RGI-C Global
  Score</span></b></p>
  <p class=TableCellCenter align=left style='margin-bottom:1.0pt;text-align:
  left;page-break-after:avoid'><span style='font-size:11.0pt'>LS Mean score
  (SE)<sup>a</sup> (positive indicates healing)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:64.45pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>40 </span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>64</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="27%" style='width:27.42%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt;height:64.45pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TableCellCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt'>+1.66 (0.1) (p&lt;0.0001)</span></p>
  <p class=TableCellCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TableCellCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt'>+1.56 (0.1) (p&lt;0.0001)</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="32%" style='width:32.52%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:64.45pt'>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>+1.47 (0.1) (p&lt;0.0001)</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>+1.58 (0.1) (p&lt;0.0001)</span></p>
  <p class=TableCellCenter style='margin-bottom:1.0pt;page-break-after:avoid'><span
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:13.5pt;margin-bottom:.0001pt;text-indent:-13.5pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>a)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:10.0pt'>The estimates of LS means and p-values are
from the generalized estimation equation model accounting for baseline RSS,
visits and regimen and its interaction.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Study UX023-CL205</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In paediatric Study UX023-CL205, burosumab was evaluated in
13&nbsp;XLH patients, aged 1 to 4&nbsp;years&nbsp;(mean 2.9 years; SD 1.1) for
40 weeks. All patients had radiographic evidence of rickets at baseline and
twelve patients had received oral phosphate and vitamin D analogues for a mean
(SD) duration of 16.7&nbsp;(14.4)&nbsp;months. This </span>conventional therapy
was discontinued 2-6 weeks prior burosumab initiation. <span lang=EN-GB>Patients
received burosumab at a dose of 0.8&nbsp;mg/kg every two weeks. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>In Study UX023-CL205, mean (SD) </span><span
lang=EN-GB style='color:black'>fasting </span><span lang=EN-GB
style='color:black'>serum phosphate concentration increased from 2.51 (0.284)
mg/dL (0.81 (0.092) mmol/L) at baseline to 3.47 (0.485) mg/dL (1.12 (0.158)
mmol/L) at Week 40. </span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>Serum alkaline phosphatase activity</span></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Mean (SD) serum total alkaline phosphatase
activity was 549 (193.8) U/L at baseline and decreased to 335 (87.6) U/L at
Week 40 (mean change: -36.3%).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><i><span
lang=EN-GB style='color:black'>Rickets Severity Score (RSS)</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>After 40
weeks of treatment with burosumab, mean total RSS improved from 2.92 (1.367) at
baseline to 1.19 (0.522),&nbsp;corresponding to a change from baseline in LS
mean (SE) change of -1.73 (0.132) (p&lt;0.0001).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><i><span lang=EN-GB>Radiographic Global Impression of Change (RGI-C) </span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>After 40 weeks of treatment with
burosumab, the LS mean (SE) RGI-C Global score was +2.33 (0.08) in all 13
patients (p &lt; 0.0001) demonstrating healing of rickets. All 13 patients were
considered RGI-C responders as defined by RGI-C global score &#8805; +2.0. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The European Medicines Agency has deferred the obligation to submit
the results of studies with </span><span lang=EN-GB>burosumab </span><span
lang=EN-GB>in one or more subsets of the paediatric population in treatment of
X-linked hypophosphataemia. See 4.2 for information on paediatric use.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicinal product has been authorised under a so-called
‘conditional approval’ scheme. This means that further evidence on this
medicinal product is awaited.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The European Medicines Agency will review new information on this
medicinal product at least every year and this SmPC will be updated as
necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Clinical efficacy in adults with XLH</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB>Study UX023-CL303</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Study UX023-CL303 is a randomised, double-blind, placebo-controlled
study in 134 adult XLH patients. The study comprised of a 24-week
placebo-controlled treatment phase followed by a 24-week open-label period
where all patients received burosumab. Oral phosphate and active vitamin D
analogues were not allowed during the study. Burosumab was administered at a
dose of 1 mg/kg every 4 weeks. The primary endpoint of this study was
normalisation of serum phosphate across the&nbsp;24-week double-blind period. 
Key secondary endpoints included worst pain as measured by the Brief Pain
Inventory (BPI) scale and stiffness and physical function as measured by the
WOMAC (</span><span lang=EN-GB>Western Ontario and McMaster Universities
Osteoarthritis)<i> </i></span><span lang=EN-GB>Index. Exploratory endpoints
included fracture and pseudofracture healing, enthesopathy, 6 Minute Walk Test,
BPI Pain interference, Brief Fatigue Inventory (BFI) worst fatigue and BFI
global fatigue score. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>At study entry, the mean age of patients was 40 years (range 19 to
66 years) and 35% were male.&nbsp;66&nbsp;patients were randomised to placebo
treatment and 68 to burosumab treatment; at baseline, mean (SD) serum phosphate
was 0.62&nbsp;(0.10)&nbsp;mmol/l [1.92</span><span style='color:black'> (0.32)
mg/dL] and </span><span lang=EN-GB>0.66&nbsp;(0.1&nbsp;mmol/l) [</span><span
style='color:black'>2.03 (0.30) mg/dL] in the placebo and burosumab groups
respectively. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>For the primary efficacy endpoint, a greater proportion of
patients treated with burosumab achieved a mean serum phosphate level above the
lower limit of normal (LLN) compared to the placebo group through week 24
(Table 5 and Figure 3).  </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:42.55pt;text-indent:-39.85pt;line-height:normal;page-break-after:
avoid'><b>Table 5: </b><b>Proportion of Adult Patients Achieving Mean Serum Phosphate
Levels Above the LLN at the Midpoint of the Dose Interval in Study UX023-CL303
(Double-Blind Period)</b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="97%"
 style='width:97.62%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="57%" valign=bottom style='width:57.24%;border:solid windowtext 1.0pt;
   border-right:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
   1.0pt;margin-left:21.0pt;text-indent:-21.0pt;line-height:normal;page-break-after:
   avoid'><b>&nbsp;</b></p>
   </td>
   <td width="22%" valign=bottom style='width:22.16%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid black 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
   margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
   page-break-after:avoid'><b>Placebo</b><br>
   <b>(N = 66)</b></p>
   </td>
   <td width="20%" valign=bottom style='width:20.62%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
   margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
   page-break-after:avoid'><b>Burosumab <br>
   (N = 68)</b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="57%" valign=top style='width:57.24%;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:1.0pt;line-height:normal;page-break-after:
  avoid'>Achieved Mean Serum Phosphate &gt;&nbsp;LLN Across Midpoints of Dose
  Intervals Through Week 24 - n (%)</p>
  </td>
  <td width="22%" valign=top style='width:22.16%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;text-align:center;
  line-height:normal;page-break-after:avoid'>7.6% (5/66)</p>
  </td>
  <td width="20%" valign=top style='width:20.62%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;text-align:center;
  line-height:normal;page-break-after:avoid'>94.1% (64/68)</p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.24%;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  0in;margin-left:.3in;margin-bottom:.0001pt;text-indent:-8.1pt;line-height:
  normal;page-break-after:avoid'>95% CI</p>
  </td>
  <td width="22%" valign=top style='width:22.16%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;text-align:center;
  line-height:normal;page-break-after:avoid'>(3.3, 16.5)</p>
  </td>
  <td width="20%" valign=top style='width:20.62%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;text-align:center;
  line-height:normal;page-break-after:avoid'>(85.8, 97.7)</p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.24%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  0in;margin-left:.3in;margin-bottom:.0001pt;text-indent:-8.1pt;line-height:
  normal;page-break-after:avoid'>p-value<sup>a</sup></p>
  </td>
  <td width="22%" valign=top style='width:22.16%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;text-align:center;
  line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width="20%" valign=top style='width:20.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;text-align:center;
  line-height:normal;page-break-after:avoid'>&lt;&nbsp;0.0001</p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span style='font-size:9.0pt'>The 95% CIs are
calculated using the Wilson score method.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><sup><span style='font-size:9.0pt'>a</span></sup><span
style='font-size:9.0pt'>       </span><span style='font-size:9.0pt'>P-value is
from Cochran-Mantel-Haenszel (CMH) testing for association between achieving
the primary endpoint and treatment group, adjusting for randomisation
stratifications.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><b>Figure 3:</b> <b><span lang=EN-GB>Mean (± SE)
Serum Phosphate Peak Concentrations (mg/dL </span></b><span lang=EN-GB>[</span><b><span
lang=EN-GB>mmol/L</span></b><span style='color:black'>]</span><b><span
lang=EN-GB>)</span></b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB><img border=0 width=605 height=449 id="Picture 10"
src="CRYSVITA%20II-10-G%20-%20EN%20annexes%20clean_files/image004.jpg"></span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><i><span lang=EN-GB>Patient reported pain, physical function and
stiffness </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Change from
baseline at Week 24 showed a larger difference for burosumab relative to
placebo in patient reported pain (BPI), physical function (WOMAC Index) and
stiffness (WOMAC Index).  The mean (SE) difference between treatment groups
(burosumab-placebo) reach statistical significance for WOMAC stiffness at Week
24.  Details are shown in Table 6.  </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span style='font-size:10.0pt'>&nbsp;</span></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-42.55pt;line-height:
normal'><b>Table 6: Patient reported pain, physical function and stiffness score
changes from baseline to Week 24 and analysis of difference at Week 24</b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><b><span style='font-size:10.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span style='font-size:10.0pt'>&nbsp;</span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=604
 style='width:453.3pt;margin-left:-.25pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=217 valign=top style='width:162.8pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:142.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>Placebo</span></b></p>
  </td>
  <td width=198 colspan=2 valign=top style='width:148.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>Burosumab</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:162.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:142.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=66</span></p>
  </td>
  <td width=198 colspan=2 valign=top style='width:148.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=68</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:162.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><i><span lang=EN-GB style='font-size:10.0pt'>BPI worst
  pain</span></i></b><sup><span style='font-size:10.0pt'>a</span></sup></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:142.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=198 colspan=2 valign=top style='width:148.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:17.65pt'>
  <td width=217 valign=top style='width:162.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.65pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-size:10.0pt'>LS
  Mean (SE) change from Baseline</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:142.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.65pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>-0.32 (0.2) </span></p>
  </td>
  <td width=198 colspan=2 valign=top style='width:148.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.65pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>-0.79 (0.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:162.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>[95% CIs]</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:142.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>[</span><span style='font-size:10.0pt'>-0.76, 0.11</span><span
  lang=EN-GB style='font-size:10.0pt'>]</span></p>
  </td>
  <td width=198 colspan=2 valign=top style='width:148.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>[</span><span style='font-size:10.0pt'>-1.20, -0.37</span><span
  lang=EN-GB style='font-size:10.0pt'>]</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:162.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt'>LS Mean (SE) Difference
  (Burosumab-Placebo)</span></p>
  </td>
  <td width=387 colspan=4 valign=top style='width:290.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>-0.5 (0.28)</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:162.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt'>p-value</span></p>
  </td>
  <td width=387 colspan=4 valign=top style='width:290.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0919</span><sup><span style='font-size:10.0pt'>c</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width=604 colspan=5 valign=top style='width:453.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><i><span style='font-size:
  10.0pt'>WOMAC Index physical function</span></i></b><sup><span
  style='font-size:10.0pt'>b</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width=218 colspan=2 valign=top style='width:163.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-size:10.0pt'>LS
  Mean (SE) change from Baseline</span></p>
  <p class=MsoNormal style='line-height:normal'><span style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>[95% CIs]</span></p>
  </td>
  <td width=193 colspan=2 valign=top style='width:144.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='font-size:10.0pt'>+1.79 (2.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>[-3.54, 7.13]</span></p>
  </td>
  <td width=194 valign=top style='width:145.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='font-size:10.0pt'>-3.11 (2.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>[-8.12, 1.89]</span></p>
  </td>
 </tr>
 <tr>
  <td width=218 colspan=2 valign=top style='width:163.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-size:10.0pt'>LS
  Mean (SE) Difference</span></p>
  </td>
  <td width=387 colspan=3 valign=top style='width:289.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='font-size:10.0pt'>-4.9 (2.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=218 colspan=2 valign=top style='width:163.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-size:10.0pt'>p-value</span></p>
  </td>
  <td width=387 colspan=3 valign=top style='width:289.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='font-size:10.0pt'>0.0478<sup>c</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=604 colspan=5 valign=top style='width:453.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><i><span style='font-size:
  10.0pt'>WOMAC Index stiffness</span></i></b><sup><span style='font-size:10.0pt'>b</span></sup></p>
  </td>
 </tr>
 <tr style='height:32.65pt'>
  <td width=218 colspan=2 valign=top style='width:163.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:32.65pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-size:10.0pt'>LS
  Mean (SE) change from Baseline</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>[95% CIs]</span></p>
  </td>
  <td width=193 colspan=2 valign=top style='width:144.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:32.65pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='font-size:10.0pt'>+0.25 (3.1) </span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='font-size:10.0pt'>[5.89, 6.39]</span></p>
  </td>
  <td width=194 valign=top style='width:145.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:32.65pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='font-size:10.0pt'>-7.87 (3.0) </span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='font-size:10.0pt'>[-13.82, -1.91</span><span lang=EN-GB
  style='font-size:10.0pt'>]</span></p>
  </td>
 </tr>
 <tr>
  <td width=218 colspan=2 valign=top style='width:163.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-size:10.0pt'>LS
  Mean (SE) Difference (Burosumab-Placebo)</span></p>
  </td>
  <td width=387 colspan=3 valign=top style='width:289.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='font-size:10.0pt'>-8.12 (3.2) </span></p>
  </td>
 </tr>
 <tr>
  <td width=218 colspan=2 valign=top style='width:163.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-size:10.0pt'>p-value</span></p>
  </td>
  <td width=387 colspan=3 valign=top style='width:289.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='font-size:10.0pt'>0.0122  </span></p>
  </td>
 </tr>
 <tr>
  <td width=604 colspan=5 valign=top style='width:453.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><sup><span style='font-size:
  9.0pt'>&nbsp;</span></sup></p>
  <p class=MsoNormal style='line-height:normal'><sup><span style='font-size:
  9.0pt'>a </span></sup><span style='font-size:9.0pt'>BPI worst pain item score
  ranges from 0 (no pain) to 10 (pain as bad as you can imagine)</span></p>
  <p class=MsoNormal style='line-height:normal'><sup><span style='font-size:
  9.0pt'>b </span></sup><span style='font-size:9.0pt'>WOMAC Index physical
  function and stiffness domains range from 0 (best health) to 100 (worst
  health)  </span></p>
  <p class=MsoNormal style='line-height:normal'><sup><span style='font-size:
  9.0pt'>c </span></sup><span style='font-size:9.0pt'>Not significant following
  Hochberg adjustment</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=217 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=189 style='border:none'></td>
  <td width=4 style='border:none'></td>
  <td width=194 style='border:none'></td>
 </tr>
</table>

<p class=BodytextAgency style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:14.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><a
name="_Ref514939359"></a><a name="_Toc514944847"><i><span lang=EN-GB>6 Minute
Walk Test</span></i></a></p>

<p class=MsoNormal><span lang=EN-GB>This exercise test was conducted in all
patients at Baseline, Week 12, 24, 36 and 48 (LS mean difference in change from
baseline, burosumab &#8594; placebo; Table 7). Improvements continued through
to Week 48 where distance walked increased from 357 m at baseline to 393 m at
Week 48. Patients who crossed over from placebo to burosumab achieved similar
improvements after 24 weeks of treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-42.55pt;page-break-after:
avoid'><b><span lang=EN-GB>Table 7: 6 Minute Walk distance (SD) Baseline and
Week 24; Least Squares Mean Difference&nbsp;(SE)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=283 valign=top style='width:2.95in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6 MWT,
  m(SD)</span></b></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  </td>
  <td width=160 valign=top style='width:120.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Burosumab</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=283 valign=top style='width:2.95in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Baseline </span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>367 (103)</span></p>
  </td>
  <td width=160 valign=top style='width:120.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>357 (109)</span></p>
  </td>
 </tr>
 <tr>
  <td width=283 valign=top style='width:2.95in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Week 24 </span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>369 (103)</span></p>
  </td>
  <td width=160 valign=top style='width:120.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>382 (108)</span></p>
  </td>
 </tr>
 <tr>
  <td width=283 valign=top style='width:2.95in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>LS Mean
  difference burosumab-placebo (SE)</span></p>
  </td>
  <td width=321 colspan=2 valign=top style='width:240.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>20 (7.7)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-42.55pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
style='color:black'>Radiographic Evaluation of Fractures and Pseudofractures</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>In Study UX023-CL303, a skeletal survey was
conducted at baseline to identify osteomalacia-related fractures and
pseudofractures. There were 52% (70/134) of patients who had either active
fractures (12%, 16/134) or active pseudofractures (47%, 63/134) at baseline.   Following
burosumab treatment more patients showed healing of fractures and
pseudofractures compared to the placebo group (Figure&nbsp;4). During the
placebo-controlled treatment period up to week 24, a&nbsp;total of 6 new
fractures or pseudofractures appeared in 68 patients receiving burosumab
compared to 8 new abnormalities in 66 patients receiving placebo. Of the number
of new fractures developed prior to week 48 most (10/18) </span><span
style='color:black'>were healed or partially healed at the end of the study.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Figure 4:  Percentage of Healed Active Fractures and Pseudofractures
in Study UX023-CL303</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><i><u><span lang=EN-GB style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'><img border=0 width=624 height=521
id="Picture 12"
src="CRYSVITA%20II-10-G%20-%20EN%20annexes%20clean_files/image005.jpg"></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><i><u><span lang=EN-GB style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><i><u><span
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><i><u><span
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>At Baseline,
the mean (SD) total calcaneal enthesopathy burden (sum of superior and inferior
calcaneal spurs) was 5.64 (3.12) cm in the burosumab group and 5.54 (3.1) cm in
the placebo group.  At Week 24, the mean (SD) total calcaneal enthesopathy
burden was 5.90 (3.56) cm in the burosumab&#8594;burosumab group and 4.07 (2.38)
cm in the placebo&#8594;burosumab group. </p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the
exploratory endpoints of BPI Pain interference, BFI worst fatigue and BFI
global fatigue score no meaningful difference were observed between treatment
arms.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><i><u><span
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><i><u><span
style='color:black'>Bone Histomorphometry in Adults</span></u></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB>Study UX023-CL304</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Study UX023-CL304 is a 48-week, open-label, single-arm study in
adult XLH patients to assess the effects of burosumab on improvement of
osteomalacia as determined by histologic and histomorphometric evaluation of
iliac crest bone biopsies. Patients received 1.0 mg/kg burosumab every 4 weeks.
Oral phosphate and active vitamin D analogues were not allowed during the
study.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>14 patients were enrolled, and at study entry, the mean age of
patients was 40 years (range 25 to 52 years) and 43% were male. After 48 weeks
of treatment in Study UX023-CL304 paired biopsies were available from 11
patients; healing of osteomalacia was observed in all ten evaluable patients as
demonstrated by decreases in osteoid volume/bone volume (OV/BV) from a mean
(SD) score of 26.1% (12.4) at baseline to 11.9% (6.6), Osteoid thickness (O.Th)
declined in 11 evaluable patients from a mean (SD) of 17.2 (4.1) micrometres to
11.6 (3.1) micrometres.  </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'> </span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Burosumab absorption from subcutaneous injection sites to blood
circulation is nearly complete. Following subcutaneous administration, the median
time to reach maximum serum concentrations (T<sub>max</sub>) of burosumab is
approximately 7-13 days. The peak serum concentration (C<sub>max</sub>) and
area under the concentration-time curve (AUC) of serum burosumab is dose
proportional over the dose range of 0.1&#8209;2.0&nbsp;mg/kg.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>In XLH
patients, the <span lang=EN-GB>observed volume of distribution of burosumab
approximates the volume of plasma</span>, suggesting limited extravascular
distribution.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Burosumab is composed solely of amino acids and carbohydrates as a
native immunoglobulin and is unlikely to be eliminated via hepatic metabolic
mechanisms. Its metabolism and elimination are expected to follow the
immunoglobulin clearance pathways, resulting in degradation to small peptides
and individual amino acids. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Due to its molecular size, burosumab is not expected to be directly
excreted. The clearance of burosumab is dependent on body weight and estimated
to be 0.290&nbsp;L/day and 0.136&nbsp;L/day in a typical adult (70&nbsp;kg) and
paediatric (30&nbsp;kg) XLH patient, respectively, with corresponding
disposition half-life (t<sub>1/2</sub>) in the serum ranging from approximately
16 to 19 days. Given the t<sub>1/2 </sub>estimates, the estimated time to reach
the plateau of steady-state exposures is approximately 67 days. </span><span
lang=EN-GB> </span>Following multiple dose administration to paediatric
subjects, observed serum trough concentrations reach a plateau by 8 weeks after
initiation of treatment.<span class=MsoCommentReference><span style='font-size:
8.0pt'> </span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Linearity/non-linearity</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Burosumab displays time-invariant pharmacokinetics that is linear to
dose over the subcutaneous dose range of 0.1 to 2.0&nbsp;mg/kg.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pharmacokinetic/pharmacodynamic relationship(s)</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>With the
subcutaneous route of administration, a direct PK-PD relationship between serum
burosumab concentrations and increases in serum phosphate concentration is
observed and well described by an E<sub>max</sub>/EC<sub>50</sub> model. Serum
burosumab and phosphate concentrations, as well as TmP/GFR, increased and
decreased in parallel and reached maximum levels at approximately the same time
point after each dose, supporting a direct PK-PD relationship. The AUC for the
change from baseline in serum phosphate, TmP/GFR and 1,25(OH)<sub>2</sub>D
increased linearly with increasing burosumab AUC.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric PK/PD</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No significant
difference has been observed in paediatric patient pharmacokinetics or
pharmacodynamics as compared with PK/PD in the adult population. Burosumab
clearance and volume of distribution are body weight dependent.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special Populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Population PK analyses using data from paediatric and adult subjects
who have XLH indicated that </span><span lang=EN-GB>age, sex, race, ethnicity,
baseline serum albumin, baseline serum alkaline phosphate, baseline serum
alanine aminotransferase, </span><span lang=EN-GB>and baseline creatinine
clearance &#8805; 49.9 mL/min, were not significant predictors of burosumab PK.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Post-Prandial
Effect on Serum Phosphate and Calcium </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effect of
burosumab on serum phosphate and calcium levels after food was investigated in
two sub-studies (Study UX023-CL301 and UX023-CL303); 13 paediatric patients (aged
&gt;3&nbsp;years) and 26 adult patients (aged 24-65 years). Serum phosphate and
calcium were measured at the end of the treatment interval in paediatric
patients and mid-interval in adults.  Blood samples were taken after a period
of fasting, and again 1-2 hours after a standardised meal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Burosumab treatment did not cause post-prandial
excursions above the age-adjusted upper limits of normal in serum phosphate or
serum calcium in any paediatric or adult subject in the sub-studies.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>Adverse
reactions in non-clinical studies with normal animals were observed at
exposures which resulted in serum phosphate concentration greater than normal
limits. These effects were consistent with an exaggerated response to the
inhibition of normal FGF23 levels resulting in a supraphysiologic increase in
serum phosphate beyond the upper limit of normal</span><span lang=EN-GB
style='color:windowtext;font-style:normal'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies in
rabbits and adult and juvenile cynomolgus monkeys demonstrated dose-dependent
elevations of serum phosphate and </span><span lang=EN-GB>1,25 (OH)<sub>2</sub>D
</span><span lang=EN-GB>confirming the pharmacologic actions of burosumab in
these species. Ectopic mineralisation of multiple tissues and organs (e.g.
kidney, heart, lung, and aorta), and associated secondary consequences (e.g.
nephrocalcinosis) in some cases, due to hyperphosphataemia, was observed in
normal animals at doses of burosumab that resulted in serum phosphate
concentrations in animals greater than approximately 8 mg/dL (2.6 mmol/L). In a
murine model of XLH, a significant reduction in the incidence of ectopic
mineralisation was observed at equivalent levels of serum phosphate, suggesting
that the risk of mineralisation is less in the presence of excess FGF23.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span
class=apple-converted-space><span lang=EN-GB style='color:black;background:
white'>Bone effects seen in adult and juvenile monkeys included changes in bone
metabolism markers, increases in thickness and density of cortical bone,
increased density of total bone and thickening of long bone. These changes were
a consequence of higher than normal serum phosphate levels, which accelerated
bone turnover and also led to </span></span><span lang=EN-GB>periosteal
hyperostosis and a decrease in bone strength in adult animals, but not <span
class=apple-converted-space><span style='color:black;background:white'>in
juvenile animals at the doses tested. </span></span>Burosumab did not promote
abnormal bone development, as no changes in femur length or bone strength were
noted in juvenile animals. <span class=apple-converted-space><span
style='color:black;background:white'>Bone changes were consistent with the
pharmacology of burosumab and the role of phosphate in bone mineralization,
metabolism and turnover.</span></span></span><span lang=EN-GB><br>
<br>
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In repeat-dose
toxicology studies of up to 40 weeks duration in cynomolgus monkeys,
mineralisation of the rete testis/seminiferous tubules was observed in male
monkeys; however, no changes were observed in semen analysis. No adverse
effects on female reproductive organs were observed in these studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In the reproductive and developmental toxicology study performed in
pregnant cynomolgus monkeys, moderate mineralisation of the placenta was seen
in pregnant animals given 30&nbsp;mg/kg of burosumab and occurred in animals
with peak serum phosphate concentration greater than approximately </span><span
lang=EN-GB>8 mg/dL (2.6 mmol/L)</span><span lang=EN-GB>. Shortening of the
gestation period and associated increased incidence of premature births were
observed in pregnant monkeys at doses of &#8805; 0.3&nbsp;mg/kg which
corresponded to burosumab exposures that are &#8805;</span><span lang=EN-GB>0.875-
to 1.39-</span><span lang=EN-GB>fold anticipated clinical levels. Burosumab was
detected in serum from fetuses indicating that </span><span lang=EN-GB>burosumab</span><span
lang=EN-GB> was transported across the placenta to the fetus. There was no
evidence of teratogenic effects. Ectopic mineralisation was not observed in
foetuses or offspring and burosumab did not affect pre- and postnatal growth
including survivability of the offspring.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In preclinical
studies, ectopic mineralisation has been observed in normal animals, most
frequently in the kidney, given burosumab at doses that resulted in serum
phosphate concentrations greater than </span><span lang=EN-GB>8 mg/dL (2.6
mmol/L). </span><span lang=EN-GB>Neither new or clinically meaningful worsening
of nephrocalcinosis nor ectopic mineralisation have been observed in clinical
trials of patients with XLH treated with burosumab to achieve normal serum
phosphate levels.&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>L-histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>D-sorbitol E420</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Polysorbate 80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>L-methionine </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochloric
acid, 10% (for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Water for
injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator (2°C to 8°C). Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in the original package in order to protect from light. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clear glass vial
with butyl rubber stopper, and aluminium seal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack size of one
vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>6.6     Special
precautions for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial is for
single use only. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not shake the
vial before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Burosumab should
be administered using aseptic technique and sterile disposable syringes and
injection needles. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.       MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Kyowa Kirin Holdings B.V.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=NL>Bloemlaan 2</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=NL>2132NP Hoofddorp</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=NL>The Netherlands </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=NL>+31 (0) 237200822 </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB><a href="mailto:medinfo@kyowakirin.com"><span style='color:windowtext'>medinfo@kyowakirin.com</span></a></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1262/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1262/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1262/003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 19 February 2018</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:  21 February 2020</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency <a href="http://www.ema.europa.eu"><span
style='color:windowtext'>http://www.ema.europa.eu</span></a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:14.0pt;margin-right:6.0pt;
margin-bottom:11.0pt;margin-left:6.35pt;text-align:center;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:6.0pt;margin-bottom:
11.0pt;margin-left:42.35pt;text-indent:-.5in;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB style='color:black'>A.    MANUFACTURER(S) OF THE
BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE </span></b></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:6.0pt;margin-bottom:
11.0pt;margin-left:42.35pt;text-indent:-.5in;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB style='color:black'>B.    CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>C.    OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>D.    CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>E.    SPECIFIC
OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL
MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:6.0pt;margin-bottom:
0in;margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A.      MANUFACTURER(S) OF THE BIOLOGICAL
ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=TitleB><span lang=EN-GB style='font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><u><span lang=EN-GB
style='color:black'>Name and address of the manufacturer(s) of the biological
active substance(s) </span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=PL
style='color:black'>Kyowa Kirin Co., Ltd.<br>
Takasaki Plant<br>
100-1 Hagiwara-machi<br>
Takasaki<br>
370-0013 Gunma<br>
JAPAN</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=PL
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><u><span lang=EN-GB
style='color:black'>Name and address of the manufacturer(s) responsible for
batch release</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>Piramal Healthcare UK Limited<br>
Whalton Road<br>
Northumberland<br>
Morpeth<br>
NE61 3YA<br>
UNITED KINGDOM</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=SV
style='color:black'>allphamed PHARBIL Arzneimittel GmbH</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=SV
style='color:black'>Hildebrandstr. 10-12</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=SV
style='color:black'>37081 Göttingen</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>GERMANY</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>The printed package leaflet of the medicinal product must
state the name and address of the</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>manufacturer responsible for the release of the concerned
batch.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:14.0pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B.      CONDITIONS OR RESTRICTIONS REGARDING
SUPPLY AND USE</span></p>

<p class=TitleB><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:14.0pt;text-autospace:
none'><span lang=EN-GB style='color:black'>Medicinal product subject to
restricted medical prescription (see Annex I: Summary of Product
Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:0in;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF
THE MARKETING AUTHORISATION </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:23.4pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:12.0pt;
font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Periodic safety update
reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>The requirements for submission of PSURs for this medicinal
product are set out in the list of Union reference dates (EURD list) provided
for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates
published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>The marketing authorisation holder (MAH) shall submit the
first PSUR for this product within 6 months following authorisation.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>D.      CONDITIONS OR RESTRICTIONS WITH REGARD
TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:23.4pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:12.0pt;
font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Risk management plan
(RMP)</span></b></p>

<p class=MsoNormal style='margin-left:23.4pt;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>The marketing authorisation holder (MAH) shall perform the
required pharmacovigilance activities and interventions detailed in the agreed
RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent
updates of the RMP.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:7.0pt;
margin-left:41.4pt;text-indent:-.25in;line-height:14.0pt;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>At the request of the
European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:7.0pt;
margin-left:41.4pt;text-indent:-.25in;line-height:14.0pt;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Whenever the risk management
system is modified, especially as the result of new information being received
that may lead to a significant change to the benefit/risk profile or as the
result of an important (pharmacovigilance or risk minimisation) milestone being
reached. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:0in;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>E.      SPECIFIC OBLIGATION TO COMPLETE
POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;text-autospace:
none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>This being a conditional marketing authorisation and
pursuant to Article 14a of Regulation (EC) No 726/2004, the MAH shall complete,
within the stated timeframe, the following measures:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=632
 style='margin-left:1.2pt;border-collapse:collapse'>
 <thead>
  <tr>
   <td width=535 valign=top style='width:401.35pt;border:solid black 1.0pt;
   background:white;padding:0in 0in 0in 0in'>
   <p class=MsoNormal style='margin-top:0in;margin-right:5.4pt;margin-bottom:
   7.0pt;margin-left:5.4pt;line-height:14.0pt;page-break-after:avoid;
   text-autospace:none'><b><span lang=EN-GB style='color:black'>Description</span></b></p>
   </td>
   <td width=97 valign=top style='width:72.6pt;border:solid black 1.0pt;
   border-left:none;background:white;padding:0in 0in 0in 0in'>
   <p class=MsoNormal style='margin-top:0in;margin-right:5.4pt;margin-bottom:
   7.0pt;margin-left:5.4pt;line-height:14.0pt;page-break-after:avoid;
   text-autospace:none'><b><span lang=EN-GB style='color:black'>Due date</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:12.5pt'>
  <td width=535 valign=top style='width:401.35pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 0in 0in 0in;height:12.5pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:7.0pt;
  margin-left:5.6pt;line-height:14.0pt'><b><span lang=EN-GB style='font-size:
  10.0pt;color:black'>UX023-CL205</span></b></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:7.0pt;
  margin-left:5.6pt;line-height:14.0pt'><span lang=EN-GB style='font-size:10.0pt;
  color:black'>In order to confirm the efficacy and safety of Crysvita in the
  treatment of X-linked Hypophosphataemia (XLH) in children between 1 and 4
  years old, the MAH should submit the updated results of study UX023-CL205, an
  open-label, phase 2 study to assess the safety, pharmacodynamics, and
  efficacy of KRN23 in paediatric patients with XLH.</span></p>
  </td>
  <td width=97 valign=top style='width:72.6pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:
  white;padding:0in 0in 0in 0in;height:12.5pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:5.4pt;margin-bottom:
  0in;margin-left:5.4pt;margin-bottom:.0001pt;text-autospace:none'><span
  lang=EN-GB style='color:black;background:yellow'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:5.4pt;margin-bottom:
  0in;margin-left:5.4pt;margin-bottom:.0001pt;text-autospace:none'><span
  lang=EN-GB style='color:black'>May 2020</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:.1pt;margin-bottom:7.0pt;
margin-left:.1pt;line-height:14.0pt;text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Courier New";color:#339966'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10&nbsp;mg CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.</span></b><b><span
lang=EN-GB>       </span><span lang=EN-GB>NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeader style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>CRYSVITA 10 mg solution
for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>burosumab</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 10 mg burosumab in 1 ml of solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
L-histidine, D- sorbitol E420, polysorbate 80, L-methionine, hydrochloric acid,
10%, and water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Subcutaneous
use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Do not shake before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.</span></b><b><span
lang=EN-GB>       </span><span lang=EN-GB>EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Store in the original package in order to protect from
light.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kyowa Kirin
Holdings B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bloemlaan 2</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2132NP Hoofddorp</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Netherlands </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1262/001</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b>13.     BATCH
NUMBER</b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Lot</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.       UNIQUE IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18.       UNIQUE IDENTIFIER - HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>PC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>SN</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>NN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10&nbsp;mg VIAL </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CRYSVITA 10 mg injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>burosumab</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SC</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.       METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.</span></b><b><span lang=EN-GB>       </span><span lang=EN-GB>BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>1 ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>20&nbsp;mg CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.</span></b><b><span
lang=EN-GB>       </span><span lang=EN-GB>NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeader style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>CRYSVITA 20 mg solution
for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>burosumab</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 20 mg burosumab in 1 ml of solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
L-histidine, D- sorbitol E420, polysorbate 80, L-methionine, hydrochloric acid,
10%, and water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Subcutaneous
use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Do not shake before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.</span></b><b><span
lang=EN-GB>       </span><span lang=EN-GB>EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Store in the original package in order to protect from
light.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kyowa Kirin
Holdings B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bloemlaan 2</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2132NP Hoofddorp</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Netherlands </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1262/002</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b>13.     BATCH
NUMBER</b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Lot</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.       UNIQUE IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18.       UNIQUE IDENTIFIER - HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>PC </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>SN </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>NN </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>20&nbsp;mg VIAL </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CRYSVITA 20 mg injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>burosumab</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SC</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.       METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.</span></b><b><span lang=EN-GB>       </span><span lang=EN-GB>BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>1 ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>30&nbsp;mg CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.</span></b><b><span
lang=EN-GB>       </span><span lang=EN-GB>NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeader style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>CRYSVITA 30 mg solution
for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>burosumab</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 30 mg burosumab in 1 ml of solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
L-histidine, D- sorbitol E420, polysorbate 80, L-methionine, hydrochloric acid,
10%, and water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Subcutaneous
use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Do not shake before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.</span></b><b><span
lang=EN-GB>       </span><span lang=EN-GB>EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Store in the original package in order to protect from
light.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kyowa Kirin
Holdings B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bloemlaan 2</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2132NP Hoofddorp</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Netherlands </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1262/003</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b>13.     BATCH
NUMBER</b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Lot</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.       UNIQUE IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18.       UNIQUE IDENTIFIER - HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>PC </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>SN </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>NN </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>30&nbsp;mg VIAL </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CRYSVITA 30 mg injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>burosumab</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SC</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.       METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.</span></b><b><span lang=EN-GB>       </span><span lang=EN-GB>BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>1 ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>CRYSVITA 10&nbsp;mg solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>CRYSVITA 20&nbsp;mg solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>CRYSVITA 30&nbsp;mg solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>burosumab</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><img border=0 width=21 height=18
id=picture
src="CRYSVITA%20II-10-G%20-%20EN%20annexes%20clean_files/image006.png"
alt="BT_1000x858px"><span lang=EN-GB>This medicine is subject to additional
monitoring. This will allow quick identification of new safety information. You
can help by reporting any side effects you may get. See the end of
section&nbsp;4&nbsp;for how to report side effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor. This includes any possible side effects not listed in this leaflet. See
section 4.</span></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.</span><span lang=EN-GB>       </span><span lang=EN-GB>What </span><span
lang=EN-GB>CRYSVITA is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.</span><span lang=EN-GB>       </span><span lang=EN-GB>What you
need to know before you use </span><span lang=EN-GB>CRYSVITA</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.</span><span lang=EN-GB>       </span><span lang=EN-GB>How to use </span><span
lang=EN-GB>CRYSVITA</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.       Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.</span><span lang=EN-GB>       </span><span lang=EN-GB>How to
store </span><span lang=EN-GB>CRYSVITA</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.       Contents of the pack and other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:28.5pt;text-indent:-28.5pt;
line-height:normal'><b><span lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What CRYSVITA is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What </span><span
lang=EN-GB>CRYSVITA is</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CRYSVITA contains
the active substance burosumab. This is a type of medicine called a human
monoclonal antibody. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is CRYSVITA used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CRYSVITA is used
to treat X-linked hypophosphataemia (XLH). It is used in children and
adolescents aged 1 to 17 years, and in adults</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is X-Linked Hypophosphataemia (XLH)</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>X-Linked Hypophosphataemia (XLH) is a genetic disease.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>People with XLH have higher levels of a hormone
called fibroblast growth factor 23 (FGF23).</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>FGF23 lowers the amount of phosphate in the
blood.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The low level of phosphate may: </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lead to bones that may not harden properly and,
in children and adolescents, cannot grow properly</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>result in pain and stiffness in bones and joints</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>How CRYSVITA works</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CRYSVITA</span><span
lang=EN-GB> attaches to FGF23 in the blood which stops FGF23 from working and</span>
increases the phosphate levels in the blood so that normal levels of phosphate
can be achieved<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:200%'><span lang=EN-GB style='line-height:
200%'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.4in;text-indent:-.4in;
line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before you use
CRYSVITA </span></b></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.5pt;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
name="_Hlk21517853"><b><span lang=EN-GB>Do not use </span></b></a><b>CRYSVITA
if</b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you are allergic to burosumab or any of the
other ingredients of this medicine (listed in section&nbsp;6) </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you are taking any phosphate supplements or certain
vitamin D supplements (that contain so called active vitamin D, e.g.
calcitriol)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you already have a high level of phosphate in
your blood (“hyper-phosphataemia”)</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have severe kidney disease or kidney
failure.</span></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u>Allergic reactions</u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Stop taking CRYSVITA and tell your doctor straight away if you have
any of the following side effects, as they could be signs of an allergic
reaction:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash and itching all over the body</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe swelling of eyelids, mouth or lips
(angio-oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>shortness of breath</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rapid heartbeat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sweating.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not take CRYSVITA
if any of the above apply to you. If you are not sure, talk to your doctor
before using CRYSVITA.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions </span></b></p>

<p class=MsoNormal style='line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal style='line-height:normal'><u>Skin reactions</u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>You may get skin
reactions where the injection is given, see section 4 for more information. If
these reactions are severe, tell your doctor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Tests and
checks</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Your doctor will
check the phosphate and calcium levels in your blood and urine and may also do
a renal ultrasound during your treatment in order to reduce the risk of
hyperphosphataemia (too much phosphate in the blood) and ectopic mineralisation
(a build-up of calcium in tissues such as the kidneys). Your serum parathyroid
hormone level will also be checked from time to time.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Children
under 1 year</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Crysvita should
not be given to children under 1 year of age</span><span lang=EN-GB> because
the safety and effects of the medicine have not been studied in this age group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk21517912"><b><span
lang=EN-GB>Other medicines and CRYSVITA</span></b></a></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor if you are taking, have recently taken, or might
take any other medicines. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not take CRYSVITA and tell your doctor if </span><span
lang=EN-GB>you are taking:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>phosphate supplements </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>certain vitamin D supplements </span><span
lang=EN-GB>(that contain so called active vitamin D, e.g. calcitriol). </span><span
lang=EN-GB>There are some vitamin D supplements you can continue or start to
use and your doctor will advise which ones these are. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Talk to your doctor before taking CRYSVITA if you are taking:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that work in the same way as calcium
in the body (“calcimimetics”). If used together they may lower blood calcium.</span></p>

<p class=MsoNormal style='margin-left:17.85pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Pregnancy and breastfeeding </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If you are pregnant or breast-feeding, think you might be pregnant
or are planning to have a baby, ask your doctor or pharmacist for advice before
taking this medicine. This is because it is not known if CRYSVITA will affect
the baby.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-family:TimesNewRomanPSMT'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>CRYSVITA is not recommended in pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If you could get pregnant, you must use an effective method of
contraception (birth control) while using CRYSVITA. You should discuss this
with your doctor.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>It is not known if </span><span lang=EN-GB>CRYSVITA</span><span
lang=EN-GB> passes into breast milk, and a risk to newborns or infants cannot
be ruled out. You should discuss this with your doctor.</span><span lang=EN-GB>
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving, riding a bike and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=EN>It
is possible that CRYSVITA could cause dizziness and affect you being able to
ride a bike, use any tools or machines or to drive. If you think you are
affected, do not ride a bike, use any tools or machines or drive, and tell your
doctor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>CRYSVITA contains sorbitol </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
contains 45.91 mg of sorbitol in each vial which is equivalent to 45.91 mg/ml. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.</span></b><b><span lang=EN-GB>       </span><span lang=EN-GB>How
to use CRYSVITA</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'>CRYSVITA<span lang=EN-GB> should be given by injection under the skin in
the arm, abdomen, buttock or thigh by a trained healthcare provider. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>How much CRYSVITA you will be given</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The dose is based on your body weight. Your doctor will
work out the right dose for you. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>CRYSVITA will be injected:</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-right:-.1pt;text-indent:-.25in;
line-height:normal;page-break-after:avoid'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>every two weeks in children and adolescents aged
1 - 17 years </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-right:-.1pt;text-indent:-.25in;
line-height:normal;page-break-after:avoid'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>every four weeks in adults</span></p>

<p class=MsoListParagraphCxSpLast style='margin-right:-.1pt;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor will perform checks to make sure that you are getting
the right dose and may change your dose if needed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The maximum dose you will be given is 90&nbsp;mg.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you have been given more </span><span lang=EN-GB>CRYSVITA than
you should </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you think that you have been given too much </span>CRYSVITA, tell
your doctor straight away<span lang=EN-GB>. </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you miss a dose of CRYSVITA</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If a dose is missed, talk to your doctor straight away. The missed
dose should be given as soon as possible and your doctor will re-arrange future
doses accordingly.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.</span></b><b><span
lang=EN-GB>       </span><span lang=EN-GB>Possible side effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Side effects in children and adolescents</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><i><span
lang=EN-GB>Very common (may affect more than 1 in 10 children and adolescents)</span></i></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tooth abscess (infection)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cough</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Headache</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Vomiting</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Diarrhoea </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Constipation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tooth decay or cavities</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rash</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain in muscles (myalgia) and hands and feet</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Reactions where the injection was given, which
may include:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:"Courier New"'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>redness or rash</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:"Courier New"'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>pain or itching</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:"Courier New"'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>swelling</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:"Courier New"'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>bleeding or bruising</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>These injection
site reactions are usually mild and occur within a day after the injection and
usually get better in around 1 to 3 days.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Low vitamin D in your blood</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><i><span lang=EN-GB>Common
(may affect up to 1 in 10 children </span><span lang=EN-GB>and adolescents</span></i></b><b><i><span
lang=EN-GB>)</span></i></b></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dizziness</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Side effects in adults</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
lang=EN-GB>Very common (may affect more than 1 in 10 adults)</span></i></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tooth abscess (infection)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Headache</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=SV style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dizziness</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Restless legs syndrome (irresistible urge to
move your legs to stop uncomfortable, painful or odd sensations in the legs
especially prior to sleep or at night time)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain in back</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Muscle spasm</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Low vitamin D in your blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><i><span
lang=EN-GB>Common (may affect up to 1 in 10 adults)</span></i></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Constipation</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Increased phosphate in your blood</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>If you get any side effects, talk to your doctor or
nurse. This includes any possible side effects not listed in this leaflet. You
can also report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext;background:lightgrey;text-decoration:none'>Appendix V</span></a>.
By reporting side effects, you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.</span></b><b><span lang=EN-GB>       </span><span lang=EN-GB>How
to store CRYSVITA</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep CRYSVITA out
of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use CRYSVITA
after the expiry date which is stated on the carton and label.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator (2°C to 8°C). Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use CRYSVITA
if it contains visible particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.</span></b><b><span lang=EN-GB>       </span><span lang=EN-GB>Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What CRYSVITA contains     </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The active substance is burosumab. Each vial contains either 10, 20
or 30 mg of burosumab.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The other
ingredients are L-histidine, D-sorbitol (E420), polysorbate 80, L-methionine,
10%, hydrochloric acid, and water for injections. (See “CRYSVITA contains
sorbitol” in section 2 for more information).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What CRYSVITA looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CRYSVITA comes
as a clear to slightly opalescent, colourless to pale yellow/brown solution for
injection in a small glass vial. Each pack contains 1 vial. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kyowa Kirin
Holdings B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=NL>Bloemlaan 2</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=NL>2132NP Hoofddorp</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=NL>The Netherlands </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><a
href="mailto:medinfo@kyowakirin.com"><span lang=NL style='color:windowtext'>medinfo@kyowakirin.com</span></a></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=NL>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Piramal
Healthcare UK Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Whalton Road</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Morpeth</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NE61 3YA</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>allphamed
PHARBIL Arzneimittel GmbH</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hildebrandstr.
10-12</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>37081 Göttingen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine has been given ‘conditional approval’. This means that
there is more evidence to come about this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The European Medicines Agency will review new information on this
medicine at least every year and this leaflet will be updated as necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: <span class=MsoHyperlink><span style='color:windowtext'>http://www.ema.europa.eu</span></span>.
There are also links to other websites about rare diseases and treatments. </span></p>

<p class=MsoNormal style='line-height:normal'><a name="page_total_master3"></a><a
name="page_total"></a><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
